Literature DB >> 16432443

Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies.

Glenn W Currier1, Rossella Medori.   

Abstract

High utilization of emergency services by patients at increased risk for agitation and aggression makes the determination of effective therapy a major concern of psychiatric care. Agitated and aggressive behavior needs to be treated rapidly and effectively to minimize the risk to both patients and staff. Traditionally, short-acting intramuscular (IM) formulations of conventional antipsychotic drugs have been preferred in the emergency setting due to their rapid onset of action and the ability to administer them to uncooperative patients. IM injections, however, may not always be the preferred option. Recently, orally administered second generation (atypical) antipsychotics have been shown to be at least as effective in managing acute agitation as conventional antipsychotic drugs, with a superior tolerability profile. The current review evaluates pharmacokinetic parameters, formulation options, and clinical efficacy data for the treatment of acute agitation or aggressive behavior with antipsychotic medications. A synthesis of data from individual clinical trials, meta-analyses, review articles, and expert consensus recommendations is used to develop a working clinical algorithm for the acute management of aggression and agitation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432443     DOI: 10.1097/00131746-200601000-00005

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  8 in total

Review 1.  Pharmacologic management of acutely agitated pediatric patients.

Authors:  Loretta Sonnier; Drew Barzman
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

Review 2.  Pharmacological control of acute agitation: focus on intramuscular preparations.

Authors:  Dan L Zimbroff
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 3.  Management of patients presenting with acute psychotic episodes of schizophrenia.

Authors:  Pierre Thomas; Köksal Alptekin; Mihai Gheorghe; Mauro Mauri; José Manuel Olivares; Michael Riedel
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

4.  Evaluation of behavioral changes and subjective distress after exposure to coercive inpatient interventions.

Authors:  Irina Georgieva; Cornelis L Mulder; Richard Whittington
Journal:  BMC Psychiatry       Date:  2012-05-30       Impact factor: 3.630

5.  Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China.

Authors:  Yu-Chen Yeh; Xin Yu; Congpei Zhang; Wei Hao; Fen Du; Dongdong Liu; Lili Yang; Xin Gao
Journal:  Gen Psychiatr       Date:  2019-01-04

Review 6.  Achievements in Thermosensitive Gelling Systems for Rectal Administration.

Authors:  Maria Bialik; Marzena Kuras; Marcin Sobczak; Ewa Oledzka
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

7.  The use of amisulpride in the treatment of acute psychosis.

Authors:  Philippe Nuss; Martina Hummer; Cédric Tessier
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

Review 8.  Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Authors:  Justin Faden; Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2019-08-07       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.